Aptinyx Inc Stock News

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to

Aptinyx Inc (APTX) shares closed today 11.5% higher than it did at the end of yesterday. The stock is currently down 13.3% year-to-date, down 21.3% over the past 12 months, and down 85.1% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $3.00 and as low as $2.49 this week.Shares closed 36.6% below its 52-week high and 45.6% above its 52-week low.Trading volume this week was 40.1% lower than the 10-day average and 45.0% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -53.6% The company's stock price performance over the past 12 months beats the peer average by -29.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities research analysts expect Aptinyx Inc. (NASDAQ:APTX) to post earnings of ($0.35) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aptinyxs earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.43). Aptinyx reported earnings of ($0.20) per share in the []

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). The Phase 2b study is designed to be well-positioned for consideration as registration-supportive, taking into account guidance received in a Type C meeting wi

According to new research study, Global Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report 2026 thinks about key breakdowns in the industry with insights about the market drivers and market restrictions. The report illuminates accumulating an all encompassing rundown

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 13, 2022 at 12:00 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco, California. A l

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to

Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.

Aptinyx Inc. (NASDAQ:APTX) CFO Ashish Khanna bought 45,000 shares of Aptinyx stock in a transaction dated Thursday, December 2nd. The shares were bought at an average cost of $2.26 per share, for a total transaction of $101,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at []

Aptinyx Inc. (NASDAQ:APTX) CFO Ashish Khanna purchased 45,000 shares of the stock in a transaction on Thursday, December 2nd. The shares were acquired at an average cost of $2.26 per share, with a total value of $101,700.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Aptinyx []

The stock price of Aptinyx Inc (NASDAQ: APTX) increased by over 9% during intraday trading today. This is why it happened.

Related Stocks: APTX ,

Charles Schwab Investment Management Inc. trimmed its holdings in Aptinyx Inc. (NASDAQ:APTX) by 80.2% during the second quarter, HoldingsChannel reports. The firm owned 17,590 shares of the companys stock after selling 71,316 shares during the period. Charles Schwab Investment Management Inc.s holdings in Aptinyx were worth $50,000 at the end of the most recent reporting []

Cubist Systematic Strategies LLC purchased a new stake in Aptinyx Inc. (NASDAQ:APTX) in the second quarter, Holdings Channel reports. The firm purchased 29,939 shares of the companys stock, valued at approximately $85,000. Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada boosted its []

Northern Trust Corp reduced its holdings in shares of Aptinyx Inc. (NASDAQ:APTX) by 58.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 189,342 shares of the companys stock after selling 269,390 shares during the quarter. Northern Trust Corps holdings in Aptinyx []